{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:40:06Z","timestamp":1784014806196,"version":"3.55.0"},"reference-count":48,"publisher":"Wiley","issue":"11P2","license":[{"start":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T00:00:00Z","timestamp":1358294400000},"content-version":"vor","delay-in-days":2633,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p>Intravenous immunoglobulin (IGIV) originally was used as prophylactic treatment of infections in patients with primary immunodeficiency disease. Today, administration of IGIV, due in large part to its immunomodulatory activity, has expanded to include a number of other disorders. Available data suggest that the accepted indications for IGIV will continue to expand. As the number of clinical applications for this therapy grows, so will market opportunities; current preparations will be modified and improved and new products introduced. Intravenous immunoglobulin therapy has improved the lives of many patients with immune\u2010related disorders. Future applications will ideally advance this paradigm further.<\/jats:p>","DOI":"10.1592\/phco.2005.25.11part2.85s","type":"journal-article","created":{"date-parts":[[2005,10,18]],"date-time":"2005-10-18T07:28:45Z","timestamp":1129620525000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Patient: Emerging Clinical Applications of Intravenous Immunoglobulin"],"prefix":"10.1002","volume":"25","author":[{"suffix":"III","given":"R. Donald","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(05)70431-4"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01409.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1246-7820(03)00035-1"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117824"},{"key":"e_1_2_1_6_2","first-page":"23","volume-title":"Intravenous immunoglobulins in clinical practice","author":"Strand V.","year":"1997"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200312001-00004"},{"key":"e_1_2_1_9_2","volume-title":"Special report series 310","author":"Medical Research Council Working Party on Hypogammaglobulinemia","year":"1974"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200216010-00005"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:22:2-3:137"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.12_suppl_6.S13"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-003-0090-6"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5503.484"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.Suppl.6"},{"issue":"1","key":"e_1_2_1_17_2","first-page":"3","article-title":"Mechanisms of action of intravenous immune globulin in immune\u2010mediated diseases","volume":"104","author":"Mouthon L.","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_1_18_2","first-page":"1656","article-title":"Fas\u2010mediated cell death in toxic epidermal necrolysis and graft\u2010versus\u2010host disease: potential for therapeutic inhibition","volume":"130","author":"French LE","year":"2000","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2001.0141"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05157-0"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-003-0089-z"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277"},{"key":"e_1_2_1_23_2","article-title":"Treatment for Lambert\u2010Easton myasthenic syndrome","volume":"2","author":"Maddison P.","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"e_1_2_1_24_2","first-page":"S2","article-title":"The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents","volume":"60","author":"Toyka KV","year":"2003","journal-title":"Neurology"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.60.8_suppl_3.S16"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001797"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118640"},{"key":"e_1_2_1_28_2","volume-title":"Present and future uses of intravenous immune globulin (IGIV): a Canadian multidisciplinary consensus\u2010building initiative, May 24, 1997","author":"Consensus Working Group","year":"1997"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00121.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000145878.92906.9F"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub2"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(02)00343-X"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-003-0083-5"},{"key":"e_1_2_1_34_2","first-page":"713","article-title":"Intravenous immunoglobulin: an emerging treatment for immune\u2010mediated skin diseases","volume":"3","author":"Rutter A.","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.8.1051"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.6.1430"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2003.00714.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200320090-00004"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520470073035"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1542\/peds.21.6.980","article-title":"Chronic asthma in childhood: double\u2010blind controlled study of treatment with gamma\u2010globulin","volume":"61","author":"Abernathy RS","year":"1958","journal-title":"Pediatrics"},{"key":"e_1_2_1_41_2","first-page":"168","article-title":"Clinical results of a prospective, double\u2010blind, placebo\u2010controlled trial of intravenous gamma\u2010globulin in children with chronic chest symptoms","volume":"23","author":"Smith TF","year":"1988","journal-title":"Monogr Allergy"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.7.662"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854101778249230"},{"key":"e_1_2_1_44_2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ajhp\/60.19.1949","article-title":"Current and emerging therapies for the management of chronic inflammation in asthma","volume":"60","author":"DeKorte CJ","year":"2003","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_45_2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001090","article-title":"Intravenous immunoglobulin for treating sepsis and septic shock","volume":"1","author":"Alejandria MM","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540310015944"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311802"},{"key":"e_1_2_1_48_2","first-page":"209","article-title":"Systematic review of the biology and medical management of respiratory syncytial virus infection","volume":"48","author":"Black CP","year":"2003","journal-title":"Respir Care"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.10.1801"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.2005.25.11part2.85S","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.2005.25.11part2.85S","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:18:25Z","timestamp":1761052705000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.2005.25.11part2.85S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":48,"journal-issue":{"issue":"11P2","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1592\/phco.2005.25.11part2.85S"],"URL":"https:\/\/doi.org\/10.1592\/phco.2005.25.11part2.85s","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"2013-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}